We agreed with the conclusions of Latasiewicz et al 1 'Hydroxychloroquine retinopathy: an emerging problem', which cited cases of hydroxychloroquine (HCQ)-induced retinal damage. Three patients had received 400 mg HCQ daily for over 15 years (equaling 4.93 mg/kg/day in two and 5.6 mg/kg/day in one) and all developed maculopathies of varying severity. The study by Latasiewicz et al 1 recommended a standardized screening protocol to monitor for retinal toxicity in patients treated with HCQ. Ocular toxicity ranged from non-significant keratopathy to a potentially blinding retinopathy as described previously with varying doses of HCQ. 1, 2 In 2016 the American Academy of Ophthalmology recommended a maximum daily HCQ use of 5.0 mg/kg, a baseline fundal examination to exclude pre-existing maculopathy and an annual screening after 5 years of HCQ use. 3 Being a synthetic antimalarial, HCQ is used for immunomodulation in autoimmune diseases. 2 Commonly used daily doses of HCQ are 200mg or 400 mg (which equals a dose of 5.3 mg/kg and 2.6 mg/kg for a 75 kg patient, respectively), and therapeutic plasma concentrations of 500-2000 ng HCQ/ml have previously been described.
The pathogenesis of HCQ-induced retinal toxicity is not fully understood. HCQ displays a high affinity to melanin containing cells in the skin, ciliary bodies, and retinal pigment epithelium (RPE). 2 Previous in vitro studies on cultured RPE cells suggest that HCQ causes retinal damage through changing RPE lysosomal pH, resulting in higher levels of lipofuscin, a pigment that commonly accumulates with age and is associated with photoreceptor degeneration. 2 Interestingly Bharadwaj et al 4 showed in vitro that leukocyte migration on retinal epithelium is linked to an increased expression of adhesion molecules (including intercellular adhesion molecule (ICAM-1)).
Our in vitro experiments are the first to link therapeutic levels of HCQ to increased ICAM-1 expression. In this model, HCQ-exposed human umbilical arterial endothelial cells are stimulated with tumor necrosis factor alpha and thrombin-activated platelets, and showed significantly elevated levels of ICAM-1 when HCQ doses of 41000 ng/ml are used (Figure 1) . These results suggest that ICAM-1 may be involved in the pathogenesis of HCQ-induced retinal toxicity. We read with special interest the retrospective cohort study by Alboim et al 1 who examined the importance of preoperative evaluation for outpatients undergoing cataract surgery. They suggested that preoperative evaluation has no role in reducing adverse events in these Figure 1 Surface expression of ICAM-1 on HUAEC with and without 24 h pre-incubation with 1000ng/ml or 2000 ng/ml HCQ. N = 7; PLT, platelets; TNFalpha, tumor necrosis factor alpha (*Po0.05, as evaluated by Dunnett's test).
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